1. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
2. PEMAZYRE™ (pemigatinib) tablets for oral use [prescribing information]. Incyte Corporation. April 2020. Accessed April 8 2021.https://www.pemazyre.com/pdf/prescribing‐information.pdf
3. Pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignancies;Ji T;Mol Cancer Ther,2019
4. Pemazyre: European Public Assessment Report – Summary of Product Characteristics. Accessed May 28 2021.https://www.ema.europa.eu/en/documents/product‐information/pemazyre‐epar‐product‐information_en.pdf
5. Incyte announces approval of Pemazyre®(pemigatinib) in Japan for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene worsening after cancer chemotherapy[press release]. Wilmington DE: Incyte Corporation; March 23 2021. Accessed July 13 2021.https://investor.incyte.com/press‐releases/press‐releases/2021/Incyte‐Announces‐Approval‐of‐Pemazyre‐pemigatinib‐in‐Japan‐for‐the‐Treatment‐of‐Patients‐with‐Unresectable‐Biliary‐Tract‐Cancer‐BTC‐with‐a‐Fibroblast‐Growth‐Factor‐Receptor‐2‐FGFR2‐Fusion‐Gene‐Worsening‐After‐Cancer‐Chemotherapy/default.aspx